The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Treatment of Acute Hepatitis C with Interferon Alfa-2b
Open accessAbstract
BACKGROUND: In people who are infected with the hepatitis C virus (HCV) chronic infection often develops and is difficult to eradicate. We sought to determine whether treatment during the acute phase could prevent the development of chronic infection. METHODS: Between 1998 and 2001, we identified 44 patients throughout Germany who had acute hepatitis C. Patients received 5 million U of interferon alfa-2b subcutaneously daily for 4 weeks and then three times per week for another 20 weeks. Serum HCV RNA levels were measured before and during therapy and 24 weeks after the end of therapy. RESULTS: The mean age of the 44 patients was 36 years; 25 were women. Nine became infected with HCV through intravenous drug use, 14 through a needle-stick injury, 7 through medical procedures, and 10 through sexual contact; the mode of infection could not be determined in 4. The average time from infection to the first signs or symptoms of hepatitis was 54 days, and the average time from infection until the start of therapy was 89 days. At the end of both therapy and follow-up, 43 patients (98 percent) had undetectable levels of HCV RNA in serum and normal serum alanine aminotransferase levels. Levels of HCV RNA became undetectable after an average of 3.2 weeks of treatment. Therapy was well tolerated in all but one patient, who stopped therapy after 12 weeks because of side effects. CONCLUSIONS: Treatment of acute hepatitis C with interferon alfa-2b prevents chronic infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Self-citationMcHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia
Rosenberg, E. S., Billingsley, J. M., Caliendo, A. M., Boswell, S. L., Sax, P. E., Kalams, S. A., & Walker, B. D. (1997) · Science · doi:10.1126/science.278.5342.1447 · Cited by 1,835
Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus
Lechner, F., Wong, D. K. H., Dunbar, P. R., Chapman, R., Chung, R. T., Dohrenwend, P., Robbins, G., Phillips, R., Klenerman, P., & Walker, B. D. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.9.1499 · Cited by 1,269
Moskophidis, D., Lechner, F., Pircher, H., & Zinkernagel, R. M. (1993) · Nature · doi:10.1038/362758a0 · Cited by 1,240
[Gastric adenocarcinoma and kidney transplantation].
Barrio, J., García-Bengoechea, M., Emparanza, J. I., & Arenas, J. I. (1998) · PubMed · Cited by 1,132
Immune control of HIV-1 after early treatment of acute infection
Rosenberg, E. S., Altfeld, M., Poon, S. H., Phillips, M. N., Wilkes, B. M., Eldridge, R. L., Robbins, G. K., D'Aquila, R. T., Goulder, P. J. R., & Walker, B. D. (2000) · Nature · doi:10.1038/35035103 · Cited by 1,002
Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin
Kenny-Walsh, E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904223401602 · Cited by 910
Takaki, A., Wiese, M., Maertens, G., Depla, E., Seifert, U., Liebetrau, A., Miller, J. L., Manns, M. P., & Rehermann, B. (2000) · Nature Medicine · doi:10.1038/75063 · Cited by 739
Self-citationAlter, H. J., & Seeff, L. B. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9505 · Cited by 736
Gerlach, J. T., Diepolder, H. M., Jung, M., Gruener, N. H., Schraut, W. W., Zachoval, R., Hoffmann, R., Schirren, C. A., Santantonio, T., & Pape, G. R. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70353-7 · Cited by 714
Self-citationEASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999
(1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80154-8 · Cited by 700
Missale, G., Bertoni, R., Lamonaca, V, Valli, A., Massari, M., Mori, C., Rumi, M. G., Houghton, M., Fiaccadori, F., & Ferrari, C. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118842 · Cited by 658
Zinkernagel, R. M. (1996) · Science · doi:10.1126/science.271.5246.173 · Cited by 651
(1997) · Hepatology · doi:10.1002/hep.510260701 · Cited by 569
Vogt, M. O., Lang, T., Frösner, G., Klingler, C., Sendl, A., Zeller, A., Wiebecke, B., Langer, B., Meisner, H., & Hess, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411202 · Cited by 502
Natural history of hepatitis C
Seeff, L. B. (1997) · Hepatology · doi:10.1002/hep.510260704 · Cited by 409
Association of Hepatitis C Virus–Specific CD8+T Cells with Viral Clearance in Acute Hepatitis C
Grüner, N. H., Gerlach, T. J., Jung, M., Diepolder, H. M., Schirren, C. A., Schraut, W. W., Hoffmann, R., Zachoval, R., Santantonio, T., Cucchiarini, M., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315450 · Cited by 365
Self-citationWiese, M., Berr, F., Lafrenz, M., Porst, H., & Oesen, U. (2000) · Hepatology · doi:10.1053/jhep.2000.8169 · Cited by 349
Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
Lam, N. P., Neumann, A. U., Gretch, D. R., Wiley, T. E., Perelson, A. S., & Layden, T. J. (1997) · Hepatology · doi:10.1002/hep.510260130 · Cited by 329
Lechner, F., Gruener, N. H., Urbani, S., Uggeri, J., Santantonio, T., Kammer, A. R., Cerny, A., Phillips, R., Ferrari, C., Pape, G. R., et al. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200009)30:9<2479::aid-immu2479>3.0.co;2-b · Cited by 312
Self-citationOrland, J. R., Wright, T. L., & Cooper, S. (2001) · Hepatology · doi:10.1053/jhep.2001.22112 · Cited by 196
Resolution of acute hepatitis C after therapy with natural beta interferon
Omata, M., Yokosuka, O., Takano, S., Kato, N., Hosoda, K., Imazeki, F., Tada, M., Ito, Y., & Ohto, M. (1991) · The Lancet · doi:10.1016/0140-6736(91)91774-o · Cited by 187
Oxenius, A., Zinkernagel, R. M., & Hengartner, H. (1998) · Immunity · doi:10.1016/s1074-7613(00)80628-7 · Cited by 162
Fried, M. W., Shiffman, M. L., Reddy, R., Smith, C., Marino, G., Goncales, F., Haeussinger, D., Diago, M., Carosl, G., Zarski, J., et al. (2001) · Gastroenterology · doi:10.1016/s0016-5085(08)80271-5 · Cited by 115
Role of the specific T‐cell response for clearance and control of hepatitis C virus
Pape, G. R., Gerlach, T., Diepolder, H. M., et al. (1999) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.1999.00006.x · Cited by 101
Interferon–α in Acute Posttransfusion Hepatitis C:. A Randomized, Controlled Trial
Viladomiu, L., Genescà, J., Esteban, J. I., et al. (1992) · Hepatology · doi:10.1002/hep.1840150504 · Cited by 95
High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C
Vogel, W., Graziadei, I. W., Umlauft, F., et al. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02087880 · Cited by 91
Takano, S., Satomura, Y., & Omata, M. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90130-9 · Cited by 78
Hwang, S., LEE, S., Chan, C.-Y., et al. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80246-7 · Cited by 73
Acute sporadic non-A, non-B hepatitis in Northeastern Brazil: Etiology and natural history
Paraná, R., Vitvitski, L., Andrade, Z. D. A., TREPO, C. G., Cotrim, H. P., Bertillon, P., SILVA, F. A. B. N. D., Silva, L. J. D. A., de Oliveira, I. R., & Lyra, L. G. (1999) · Hepatology · doi:10.1002/hep.510300143 · Cited by 42
Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial.
Calleri, G., Colombatto, P., Gozzelino, M., et al. (1998) · PubMed · Cited by 38
Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis.
Tassopoulos, N., Koutelou, M. G., Papatheodoridis, G., et al. (1993) · Gut · doi:10.1136/gut.34.2_suppl.s130 · Cited by 31
The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha
Palmović, D., Kurelac, I., & Crnjaković-Palmović, J. (1994) · Infection · doi:10.1007/bf01716714 · Cited by 21
Cited by
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Lai, C. L., Ratziu, V., Yuen, M.-F., & Poynard, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15108-2 · Cited by 1,727
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Metadata
- Authors
- Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C., & Manns, M. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-11-15
- Volume
- 345
- Issue
- 20
- Pages
- 1452-1457
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1996810729
- Cited by
- 800
- References
- 37
- FWCI
- 48.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.